Regional Growth

Regional Growth Co., Ltd. is a Japanese biotechnology company and a subsidiary of Healios K.K., established to promote the regional expansion and commercialization of regenerative medicine. The company focuses on the development and delivery of cell-based therapies, particularly leveraging the MultiStem (HLCM051) platform for critical care indications such as acute respiratory distress syndrome (ARDS) and ischemic stroke. Regional Growth operates as a specialized vehicle to manage the business operations, logistics, and regional partnerships necessary to bring advanced regenerative treatments to patients across Japan. By integrating clinical development with regional healthcare infrastructure, the company aims to establish a sustainable ecosystem for next-generation cell therapies.